Role for drug transporters beyond tumor resistance: Hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity

Journal of Clinical Oncology

Volumn 24, Issue 26, 2006, Pages 4225-4227

  Kroetz, Deanna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DIGLYCINE TECHNETIUM TC 99M; DISOFENIN TC 99M; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; CARRIER PROTEIN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER;

AREA UNDER THE CURVE; COLORECTAL CANCER; DIARRHEA; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; EDITORIAL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMAGING SYSTEM; LIVER DYSFUNCTION; MULTIDRUG RESISTANCE; NEUTROPENIA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TUMOR RESISTANCE; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; NOTE; PREDICTION AND FORECASTING; SCINTISCANNING; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS;

EID: 33748994272     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.2355     Document Type: Editorial

References (27)

1. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194, 2001
2. Ratain MJ: Irinotecan closing: Does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol 20:7-8, 2002
3. McLeod HL, Watters JW: Irinotecan pharmacogenetics: Is it time to intervene? J Clin Oncol 22:1356-1359, 2004
4. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
5. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000
6. Iyer L, Das S, Janisch L, et al; UGT1A1 "28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002
7. Marcuello E, Altes A, Menoyo A, et al: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682, 2004
8. Rouits E, Boisdron-Celle M, Dumont A, et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159, 2004
9. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
10. Iyer L, Hall D, Das S, et al: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582, 1999
11. Chen ZS, Furukawa T, Sumizawa T, et al: ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55:921-928, 1999
12. Luo FR, Paranjpe PV, Guo A, et al: Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos 30:763-770, 2002
13. Iyer L, Ramirez J, Shepard DR, et al: Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 49:336-341, 2002
14. Schellens JH, Maliepaard M, Scheper RJ, et al: Transport of topoisomerase I inhibitors by the breast cancer resistance protein: Potential clinical implications. Ann N Y Acad Sci 922:188-194, 2000
15. Nozawa T, Minami H, Sugiura S, et al: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439, 2005
16. Michael M, Thompson M, Hicks RJ, et al: The relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol 24:4228-4235, 2006
17. Krishnamurthy GT, Turner FE: Pharmacokinetics and clinical application of technetium 99m-labeled hepatobiliary agents. Semin Nucl Med 20:130-149, 1990
18. Hendrikse NH, Kuipers F, Meijer C, et al: In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother Pharmacol 54:131-138, 2004
19. 99mTc-HIDA cholesintigraphy in Dubin-Johnson and Rotor syndromes. Radiology 142:743-746, 1982
20. Pinos T, Figueras C, Herranz R: Scintigraphic diagnosis of Dubin-Johnsn syndrome: DISIDA is also useful. Am J Gastroenterol 86:1687-1688, 1991
21. Elferink RO, Groen AK: Genetic defects in hepatobiliary transport. Biochim Biochim Biophys Acta 1586:129-145, 2002
22. Chen CC, Meadows B, Regis J, et al: Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 3:545-552, 1997
23. Slapak CA, Dahlheimer J, Piwnica-Worms D: Reversal of multidrug resistance with LY335979: Functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo. J Clin Pharmacol 29S-38S, 2001 (suppl)
24. Litman T, Druley TE, Stein WD, et al: From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959, 2001
25. Bosma PJ, Chowdhury JR, Bakker C, et al: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175, 1995
26. Wang D, Johnson AD, Papp AC, et al: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693-704, 2005
27. Pauli-Magnus C, Kroetz DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21:904-913, 2004